BioSpace News Archive

Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.

The 2024 Annual Meeting of the American Society of Clinical Oncology, a significant event in the global oncology community, was grandly held in Chicago, USA, from May 31 to June 4, 2024.

TFF Pharmaceuticals, Inc. today announced that the Company has engaged Outcome Capital as a strategic advisor for the purpose of evaluating potential corporate partnerships and licensing opportunities.

Lyell Immunopharma, Inc. today announced initial clinical and translational data from its Phase 1 trial of LYL797, its first-generation reprogrammed ROR1 CAR T‑cell product candidate enhanced with proprietary anti-exhaustion technology.

Tiziana Life Sciences, Ltd. today announced that the U.S. Food and Drug Administration (FDA) has allowed intranasal foralumab to be used under an Expanded Access (EA) IND in its first patient with moderate Alzheimer’s disease.

We’re excited to announce today that we have closed $380 million for our latest fund, bringing the total funds raised by Curie.Bio to nearly $1 billion.

Star Therapeutics today announced the presentation of clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers.

Intellia Therapeutics, Inc. today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, receives positive feedback on its recent patent application for a new type of personalized vaccine targets, underscoring its novelty and inventiveness.

Theratechnologies Inc. Today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.